Kristin Leigh Bixel, MD
Obstetrics/Gynecology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: James Cancer Hospital & Solove Research Institute · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bixel’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$51,232
Medicare paid this office $51,232 for 122 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 21 | $5,611 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $4,396 | $57 |
| New patient visit (60+ min) | 29 | $3,522 | $121 |
| Short return visit (20+ min) | 24 | $1,287 | $42 |
| Return visit (30+ min) | 16 | $1,026 | $60 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
122 Original Medicare patients in 2024. Average age 72 · Women 100% · Also on Medicaid 18% · Health risk score 2.11. Sicker patients than 9 in 10 peers; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 75% · Cancer 52% · Depression 37% · Chronic kidney disease 36% · Diabetes 30% · Coronary heart disease 24% · Atrial fibrillation 20% · Heart failure 16% · COPD 15% · Dementia 9%.
The office billed $256,546, Medicare allowed $66,442 and paid $51,232; for 342 services of 46 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 122 | 342 | 72 | 2.11 | $256,546 | $51,232 |
| 2023 | 154 | 424 | 70 | 2.05 | $237,465 | $53,379 |
| 2022 | 84 | 203 | 69 | 1.92 | $135,425 | $31,259 |
| 2021 | 172 | 450 | 70 | 1.99 | $300,794 | $69,112 |
| 2020 | 137 | 375 | 71 | 2.21 | $213,509 | $47,156 |
| 2019 | 150 | 461 | 68 | 2.11 | $270,008 | $65,013 |
| 2018 | 138 | 399 | 69 | 2.21 | $284,222 | $62,841 |
| 2017 | 31 | 59 | 67 | 1.42 | $42,733 | $9,260 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 26 | $9,049 | $104 |
| New patient visit (60+ min) | 36 | $4,659 | $129 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $2,706 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,558 | $59 |
| Return visit (30+ min) | 31 | $2,403 | $60 |
| Short return visit (20+ min) | 36 | $1,571 | $39 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 22 | $1,072 | $36 |
| Hospital discharge day management, 30 minutes or less | 15 | $1,052 | $62 |
2022: 4 services
| Long return visit (40+ min) | 15 | $4,260 | $109 |
| New patient visit (60+ min) | 14 | $1,889 | $135 |
| Short return visit (20+ min) | 23 | $1,164 | $47 |
| Return visit (30+ min) | 16 | $1,032 | $61 |
2021: 10 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 18 | $13,025 | $724 |
| Long return visit (40+ min) | 14 | $6,302 | $107 |
| New patient visit (60+ min) | 40 | $5,581 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $3,470 | $57 |
| Return visit (30+ min) | 31 | $3,220 | $72 |
| Short return visit (20+ min) | 40 | $2,392 | $47 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,855 | $103 |
| Imaging of lymph nodes during surgery | 15 | $1,679 | $112 |
| Hospital discharge day management, 30 minutes or less | 11 | $744 | $57 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $459 | $31 |
2020: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $4,137 | $58 |
| Return visit (30+ min) | 45 | $3,852 | $57 |
| New patient visit (60+ min) | 29 | $3,270 | $113 |
| Long return visit (40+ min) | 15 | $3,065 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,674 | $111 |
| Short return visit (20+ min) | 18 | $565 | $28 |
2019: 8 services
| Long return visit (40+ min) | 23 | $5,654 | $79 |
| Return visit (30+ min) | 45 | $4,483 | $56 |
| New patient visit (60+ min) | 36 | $4,312 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 37 | $4,259 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,488 | $106 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,266 | $55 |
| Short return visit (20+ min) | 18 | $889 | $40 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $593 | $31 |
2018: 7 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 16 | $10,966 | $685 |
| New patient visit (60+ min) | 57 | $7,218 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $5,027 | $56 |
| Long return visit (40+ min) | 17 | $3,843 | $80 |
| Return visit (30+ min) | 30 | $2,846 | $54 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,070 | $103 |
| Other procedure on lymphatic system | 14 | $829 | $59 |
2017: 1 service
| New patient visit (60+ min) | 14 | $1,684 | $120 |
Medicaid work
$1,296 in 2021
Medicaid paid $1,296 for 25 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit | 13 | $757 |
| OFF/OP EST MAY X REQ PHY/QHP | 12 | $539 |
| 2021 | 25 | 2 | 12 | $1,296 |
| 2019 | 25 | 1 | 13 | $1,197 |
| 2018 | 16 | 1 | 13 | $1,157 |
See the largest Medicaid services in earlier years
2019
| OFF/OP EST MAY X REQ PHY/QHP | 25 | $1,197 |
2018
| OFF/OP EST MAY X REQ PHY/QHP | 16 | $1,157 |
Money from drug and device companies
$18 in 2025
| 2025 | 1 | 1 | None | $18 |
| 2024 | 2 | 2 | None | $46 |
| 2023 | 3 | 4 | None | $162 |
| 2022 | 1 | 1 | None | $199 |
| 2021 | 1 | 1 | None | $85 |
| 2020 | 1 | 1 | None | $58 |
| 2019 | 1 | 1 | None | $28 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $18 | 1 payment
|
See the published payment
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-31 | Lynparza | $18 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $46
| Jazz Pharmaceuticals | Zepzelca | $30 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $16 | 1 payment
|
2023: $162
| AstraZeneca Pharmaceuticals LP | Lynparza | $118 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $29 | 1 payment
|
| Dilon Technologies | Hemoblast Bellows | $15 | 1 payment
|
2022: $199
| Genentech | None | $199 | 1 payment
|
2021: $85
| AstraZeneca Pharmaceuticals LP | Lynparza | $85 | 1 payment
|
2020: $58
| Novocure | Oncology | $58 | 1 payment
|
2019: $28
| Merck Sharp & Dohme | Keytruda | $28 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With Or Without Pembrolizumab for the Treatment of High-Risk, Locally Advanced Cervical Cancer Keynote-A18 , Engot-Cx11,Gog-3047 · 2021 | Their institution | $237,532 |
| Merck Sharp & Dohme LLC · A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With Or Without Pembrolizumab for the Treatment of High-Risk, Locally Advanced Cervical Cancer Keynote-A18 , Engot-Cx11,Gog-3047 · 2022 | Their institution | $134,560 |
| Merck Sharp & Dohme LLC · A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With Or Without Pembrolizumab for the Treatment of High-Risk, Locally Advanced Cervical Cancer Keynote-A18 , Engot-Cx11,Gog-3047 · 2023 | Their institution | $94,740 |
| Seagen Inc. · A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Vs Investigator'S Choice Chemotherapy in Second- Or Third-Line Recurrent Or Metastatic Cervical Cancer · 2021 | Their institution | $45,000 |
| Merck Sharp & Dohme Corporation · A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With Or Without Pembrolizumab for the Treatment of High-Risk, Locally Advanced Cervical Cancer Keynote-A18 , Engot-Cx11,Gog-3047 · 2020 | Their institution | $40,340 |
| Merck Sharp & Dohme LLC · A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With Or Without Pembrolizumab for the Treatment of High-Risk, Locally Advanced Cervical Cancer Keynote-A18 , Engot-Cx11,Gog-3047 · 2024 | Their institution | $15,803 |
| Seagen Inc. · A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Vs Investigator'S Choice Chemotherapy in Second- Or Third-Line Recurrent Or Metastatic Cervical Cancer · 2022 | Their institution | $5,071 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 95.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1801023122
- Licence
- OH 35123675
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-06-12
- NPI last updated
- 2024-11-11
- NPI record certified
- 2024-11-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1145 Olentangy River Rd Ste 2100, Columbus, OH, 43212 · 300 Pasteur Dr, Stanford, CA, 94305
This office lists an electronic records connection.